Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369030 · ClinicalTrials.gov registry record
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
A clinical trial of Major Depressive Disorder, sponsored by Pamlab.
- Completed
- Registry status
- 554
- Enrollment target
- 2
- Study locations
NCT01369030: Completed study of Major Depressive Disorder, sponsored by Pamlab.
NCT01369030 is a study of Major Depressive Disorder that has completed, run by Pamlab. The registered enrollment target is 554 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (48% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01369030, a study of Major Depressive Disorder, has completed, sponsored by Pamlab.
- COMPLETED
- Registry status
- 554 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®. The purpose of this study is to increase the understanding of the role of L-methylfolate among patients who are candidates for Deplin®, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for depression.
Primary Outcome
The PHQ-9 is a depression scale used to assess brief depression severity by rating symptoms and functional impairment experienced in the last two weeks. The questionnaire contains a total of 9 questions, and each question is scored on a range from 0-3. The minimum value "0" represents not at all, "1" several days, "2" indicates more than half the days, and the maximum value "3" stands for nearly every day. The total possible range is 0-27. The total number of each 0, 1, 2, 3 is added and multipl
Conditions Studied
Interventions
- OTHER Deplin®
Study Locations (2)
North Carolina
- Moses Cone Family Practice Center - Greensboro
Tennessee
- Vanderbilt University School of Medicine - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-04 |
What the finished NCT01369030 record still lists
NCT01369030 is an observational study that tracks outcomes without assigning an intervention. The registered 554 participants enrollment target is mid-sized for trials with a published cap, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Deplin® is the first listed.
NCT01369030 reports a single indexed study location in North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01369030 about?
NCT01369030 is a clinical study titled "Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)". This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®. The purpose of this study is to increase the understanding of the role of L-methylfolate among patients who are candidates for ...
What is the current status of trial NCT01369030?
This trial is currently completed. The enrollment target is 554 participants. The study started on 2010-11. Estimated completion is 2012-04.
What conditions does trial NCT01369030 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01369030?
The interventions under investigation include: Deplin® (OTHER).
Who is sponsoring clinical trial NCT01369030?
This trial is sponsored by Pamlab, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01369030 being conducted?
This trial has 2 study locations across North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01369030's enrollment target sits among peer trials
554 26th of 282 higher than 257 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia